CFT7455

Cemsidomide
DEVELOPMENT STEP phase-2
SPONSOR MATRIX C4 Therapeutics [CCCC]
MECHANISM TARGET IKZF1/3

[THERAPEUTIC_PROFILE]

Target Indications

Multiple Myeloma

Mechanism Abstract

A small molecule protein degrader

[3D_INTERACTIVE_CONFORMATION]

PUBCHEM CID: 155207651
INTERACTIVE_3D_CONFORMATION
INITIALIZING_STRUCTURAL_BIOMATRIX...

[CLINICAL_TRIALS_REGISTRY]

TOTAL EXTRACTED3
RECRUITING STATUS2
COMPLETED RUNS0
REGISTRY & PHASE
TESTED CONDITION
STUDY TITLE & LIFECYCLE TIMELINES
STATUS
➔
P-2NCT07284758
Multiple MyelomaRelapsed/Refractory Multiple Myeloma
N=100Est. Finish: 2030-03
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
recruiting
➔
P-1NCT07280013
Multiple Myeloma (MM)
N=60Est. Finish: 2029-06
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
recruiting
➔
P-1NCT04756726
Multiple MyelomaLymphoma, Non-Hodgkin's
N=224Est. Finish: 2026-12-31
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
active not recruiting

[BIOCHEMICAL_STRUCTURE_REGISTRY]

MOLECULAR FORMULAC28H27N3O4
MOLECULAR WEIGHT469.5 g/mol
PARTITION (XLogP)2.9
H-BOND DONORS1
H-BOND ACCEPTORS5
COMPLEXITY SCORE819
SMILES (CANONICAL / ISOMERIC)
C1CC(=O)NC(=O)[C@H]1N2C3=C4C(=C(C=C3)CC5=CC=C(C=C5)CN6CCOCC6)C=CC=C4C2=O
INCHI KEYMUKCJOOKCZSQNW-DEOSSOPVSA-N
3D_CONFORMER_VIEWPORT
View Registry Record in PubChem [CID: 155207651] →